Baudax Bio

Baudax Bio, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for acute care settings. The company was founded in 2015 and is headquartered in Malvern, PA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baudax Bio, Inc. (NASDAQ:BXRX ) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Sam Martin - Investor Relations Gerri Henwood - President and CEO Conference Call Participants Greg Aurand - Noble Capital Operator Good morning. And welcome to the Baudax Bio First Quarter 2022 Financial Results Conference Call.

Baudax Bio, Inc.'s (BXRX) CEO Gerri Henwood on Q1 2022 Results - Earnings Call Transcript

Annual Meeting to be reconvened on May 18, 2022 Annual Meeting to be reconvened on May 18, 2022

Baudax Bio Announces Date of Reconvened Annual Meeting of Shareholders

ANJESO ® Net Product Revenue Up 113% Compared to Same Period in Prior Year; Sixth Consecutive Quarter of Demand Growth

Baudax Bio Reports First Quarter 2022 Financial Results and Business Highlights

MALVERN, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022. Baudax Bio will host a conference call and webcast at 8:30 a.m. ET on Thursday, May 5, 2022, to discuss the financial results and recent operational highlights.

Baudax Bio to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022

Baudax Bio, Inc. (BXRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Baudax Bio, Inc. (BXRX) a New Strong Buy Stock

Baudax Bio, Inc. (BXRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why Baudax Bio, Inc. (BXRX) Could be Great Choice for a Bottom Fisher

ANJESO End User Demand and Revenue Increases Four Quarters In A Row

Baudax Bio Reports 2021 Fourth Quarter and Annual Financial Results

MALVERN, Pa., March 07, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, announced that the Company received a letter on March 3, 2022 from The Nasdaq Stock Market noting the Company has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), which requires the Company to maintain a minimum closing bid price of $1.00 per share. Nasdaq staff made this determination of compliance after the Company's bid price closed above $1.00 per share for 10 consecutive business days from February 16, 2022 to March 2, 2022, and has now deemed the matter closed.

Baudax Bio Regains Compliance with NASDAQ Listing Requirements

MALVERN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, announced the pricing of its previously announced underwritten public offering of 3,508,772 shares of common stock (or common stock equivalents), together with warrants to purchase up to an aggregate of 3,508,772 shares of common stock (the “Offering”). Each share of common stock (or common stock equivalent) is being sold together with one warrant to purchase one share of common stock at a combined public offering price of $2.85 per share of common stock and accompanying warrant, less the underwriting discounts and commissions. The warrants have an exercise price of $3.25 per share, are exercisable immediately, and will expire five years following the date of issuance. The Offering is expected to close on or about March 1, 2022, subject to the satisfaction of customary closing conditions.

Baudax Bio Announces Pricing of $10.0 Million Public Offering

MALVERN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, announced it has commenced a proposed underwritten public offering of shares of common stock (or common stock equivalents), together with warrants to purchase its shares of common stock (the “Offering”). In addition, the Company intends to grant the underwriter an option to purchase additional shares and/or warrants at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock (or common stock equivalents) and warrants to be sold in the Offering are to be offered by the Company. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.

Baudax Bio Announces Proposed Public Offering of Securities

A 1-for-35 reverse stock split of Baudax Bio Inc (NASDAQ: BXRX) has gone into effect. These are the details.

Baudax Bio (BXRX) Stock: 1-For-35 Reverse Stock Split Goes Into Effect

MALVERN, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that the Company's Board of Directors has approved a 1-for-35 reverse stock split of its common shares (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern time on February 16, 2022 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company's existing trading symbol “BXRX”. At such time, the Company's common stock will also commence trading under a new CUPSIP number, 07160F206.

Baudax Bio Announces 1-for-35 Reverse Stock Split

Aridis Pharmaceuticals

Progenity

WiMi Hologram Cloud

Are these penny stocks on your watchlist for next week? The post Can These Penny Stocks Climb This Week?

Can These Penny Stocks Climb This Week? 4 To Watch Right Now

Air Industries Group

Marker Therapeutics Inc

Penny stocks to watch today The post 3 Penny Stocks Under $1 For You List This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks Under $1 For You List This Week

MALVERN, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at the H.C. Wainwright BIOCONNECT Virtual Conference being held January 10 - 13, 2022.

Baudax Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

MALVERN, Pa., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that the Compensation Committee of Baudax Bio's Board of Directors approved inducement grants of stock options to purchase an aggregate of 109,250 shares of Baudax Bio's common stock and restricted stock units covering 31,900 shares of Baudax Bio's common stock to 14 newly-hired employees, with a grant date of December 29, 2021. The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with Baudax Bio.

Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 42,289.3 shares of convertible preferred stock and warrants to purchase up to an aggregate of 12,686,790 shares of common stock for gross proceeds of $4.2 million in a registered direct offering. The shares of preferred stock will have a stated value of $100 per share and are convertible after the closing date into an aggregate of 16,915,720 shares of common stock at a conversion price of $0.25 per share. The warrants have an exercise price of $0.32 per share, will become exercisable six months following the date of issuance, and will expire 5 years following the initial exercise date. The closing of the offering is expected to occur on or about December 28, 2021, subject to the satisfaction of customary closing conditions.

Baudax Bio Announces $4.2 Million Registered Direct Offering

MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced Gerri Henwood, the Company's President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held November 29 – December 2, 2021.

Baudax Bio to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

BX-1000 Completes Dose-Escalation Study; Was Generally Well Tolerated and Rapidly Achieved Muscle Paralysis, Along with Complete Spontaneous Recovery

Baudax Bio Announces Clinical Program Update for Neuromuscular Blocking Agents BX-1000, BX-2000 and BX-3000

Baudax Bio, Inc. (BXRX) CEO Gerri Henwoodon Q3 2021 Results - Earnings Call Transcript

ANJESO ® Revenue Up 40% in Q3 2021 over Q2 2021 and Up Over 300% in Q3 2021 over Q3 2020

Baudax Bio Reports Third Quarter 2021 Financial Results and Business Highlights

MALVERN, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that management will give a corporate presentation followed by a question and answer session at the NobleCon Pain Management Investor Forum being held virtually on Thursday, October 7, 2021.

Baudax Bio to Present at the NobleCon Pain Management Investor Forum

MALVERN, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will participate in a virtual fireside chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021 at 1:15 p.m. ET.

Baudax Bio to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Baudax Bio has been a miserable investment so far as the share price remains under $1.00 per share and the market cap continues to deteriorate. The company recently reported abysmal Q2 earnings with a big miss on EPS and revenue. However, the company did reveal some encouraging commercial trends that are not evident in financials.

Baudax Bio: Looking For A Turnaround In Strong COVID-19 Headwinds

MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021.

News for Baudax Bio Stock (BXRX)